OSLER-1: Long-term LDL-lowering data on evolocumab
Final data from the OSLER-1 study on evolocumab have been published in the Journal of the American College of Cardiology. These are the longest duration lipid-lowering data reported to date showing effective reduction of LDL-C between 50-60% across a wide range of patient phenotypes and genotypes at high and very-high risk. Professors John Chapman and Henry Ginsberg note the significant impact of this study in an accompanying editorial.
